Optic Nerve Head Strain in Non-glaucoma Subjects

NCT07425535 | Not Yet Recruiting Early Phase 1

• 2 other identifiers: IRB00541877R01EY036042
• Study Type: interventional
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Persons who do not have glaucoma will have pictures taken of the optic nerve with a standard camera before and 2 weeks after starting to take a daily glaucoma eye drop to lower eye pressure. These data will be used to compare to the same procedure performed with glaucoma patients to study how glaucoma injures the eye.

Conditions

Glaucoma

Keywords

optic nerve; biomechanical strain; normal eye; glaucoma

Outcome Measures

Primary Outcomes (1)

• Optic nerve head strain

  Biomechanical strain measured by optical coherence tomography

  up to 1 month

Study Arms (1)

Study group

EXPERIMENTAL

The participants will take an approved glaucoma eye drop, latanoprost, for less than one month, with pictures of the eyes at baseline and while taking the drop.

Drug: Latanoprost (0.005%)

Interventions

Latanoprost (0.005%) DRUG

Participants take the eye drop daily for less than one month

Study group

Eligibility Criteria

• Age: 30 Years - 90 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Adults who have no history of OAG
• Have an ocular examination by a glaucoma specialist with no indications of OAG
• Have normal optical coherence tomography findings in the retinal nerve fiber layer.
• Over age 30 will be included from
• Both sexes
• All ethnic groups.
• Optic neuropathy.
• Both suspects and those with glaucoma damage will be included.

You may not qualify if:

• in whom sitting in an upright position is impossible due to physical disability
• with ocular media opacity, corneal scarring, cataract or vitreous hemorrhage, that does not allow adequate imaging resolution.
• in whom keeping the eyes open during the imaging procedure is not possible or uncomfortable.
• who cannot perform home tonometry accurately at certification
• who do not have reliable clinical Optical Coherence Tomography (OCT) testing.
• with any form of glaucoma
• with high myopia defined as refractive error \> -8
• with past keratorefractive surgery, corneal dystrophy, or corneal ectasia that would make self-tonometry measurements difficult to interpret
• inability to understand English or with a language or hearing impairment

Sponsors & Collaborators

• Johns Hopkins University: lead
• National Eye Institute (NEI): collaborator

MeSH Terms

Conditions

Glaucoma

Interventions

Latanoprost

Condition Hierarchy (Ancestors)

Ocular Hypertension; Eye Diseases

Intervention Hierarchy (Ancestors)

Prostaglandins F, Synthetic; Prostaglandins, Synthetic; Prostaglandins; Eicosanoids; Fatty Acids, Unsaturated; Fatty Acids; Lipids; Autacoids; Inflammation Mediators; Biological Factors

Study Officials

• Harry Quigley, MD

  Johns Hopkins University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Harry A Quigley, MD

CONTACT

410 955 6051; hquigley@jhmi.edu

Farzaneh Dadvar, MD

CONTACT

fdadvar1@jh.edu

Study Design

• Study Type: interventional
• Phase: early phase 1
• Allocation: NA
• Masking: NONE
• Masking Details: Biostatistician
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 16, 2026
• First Posted: February 23, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): March 1, 2028
• Study Completion (Estimated): March 31, 2028
• Last Updated: April 8, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share